Lipid-Lowering Responses to Dyslipidemia Determine the Efficacy on Liver Enzymes in Metabolic Dysfunction-Associated Fatty Liver Disease with Hepatic Injuries: A Prospective Cohort Study

PURPOSE: Effective treatment of dyslipidemia with lipid-lowering agents is pivotal in the management of metabolic-associated fatty liver disease (MAFLD) for preventing cardiovascular complications. We explored the associations between improvements in liver injuries indicated by changes in transamina...

Descripción completa

Detalles Bibliográficos
Autores principales: Liao, Xianhua, Ma, Qianqian, Wu, Tingfeng, Shao, Congxiang, Lin, Yansong, Sun, Yanhong, Feng, Shiting, Wang, Wei, Ye, Junzhao, Zhong, Bihui
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Dove 2022
Materias:
Original Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9030404/
https://www.ncbi.nlm.nih.gov/pubmed/35464261
http://dx.doi.org/10.2147/DMSO.S356371

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9030404/
https://www.ncbi.nlm.nih.gov/pubmed/35464261
http://dx.doi.org/10.2147/DMSO.S356371

Ejemplares similares